Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.70 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.70 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.50 |
| ▸ | TK2 | O00142 | 2/20 | 0.50 |
| ▸ | CD69 | Q07108 | 1/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6061102 | 1.00 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL5561744 | 1.00 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL703999 | 1.00 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16340739 | 1.00 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1495212 | 0.92 | SLC28A1 (0.65) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16808980 | 0.91 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10703036 | 0.91 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10703042 | 0.91 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6226229 | 0.91 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6545745 | 0.91 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618064-B2 | Acetylated ribonucleic acids and uses thereof | HELIX NANOTECHNOLOGIES INC (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250129364-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2025-04-24 | — | — | US | disclosed |
| EP-4519280-A2 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | Helix Nanotechnologies Inc (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12215317-B2 | Acetylated ribonucleic acids and uses thereof | HELIX NANOTECHNOLOGIES INC (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2023-11-30 | — | — | US | disclosed |
| WO-2023215516-A2 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215317-B2 | Acetylated ribonucleic acids and uses thereof | NSUN2, NSUN3, ADAR | SLC28A1 988/4885SLC28A2 719/4885SLC29A1 933/4885 |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | NSUN2, NSUN3, ADAR | SLC28A1 988/4885SLC28A2 719/4885SLC29A1 933/4885 |
| US-12618064-B2 | Acetylated ribonucleic acids and uses thereof | RNMT, TRDMT1, TRMT1L | SLC28A1 1016/4885SLC28A2 661/4885SLC29A1 800/4885 |
| US-20250129364-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | NSUN2, NSUN3, ADAR | SLC28A1 988/4885SLC28A2 719/4885SLC29A1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.